No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DGX240517C115000
- 12.10
- 0.000.00%
15min DelayTrading Feb 20 13:18 ET
0.00High0.00Low
0.00Open12.10Pre Close0 Volume13 Open Interest115.00Strike Price0.00Turnover0.00%IV0.00%PremiumMay 17, 2024Expiry Date22.00Intrinsic Value100Multiplier8DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma6.23Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- 1D
News
Quest Diagnostics to Speak at the 2024 Leerink Partners Healthcare Crossroads Conference
Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will...
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
Express News | Quest Diagnostics Inc: Pathai Will Continue to Support Its Biopharmaceutical Clients at Its Biopharma Lab
Express News | Quest Diagnostics Inc: Under Terms of Merger, Quest Will Buy Anatomic and Digital Pathology Laboratory Services of Pathai
Express News | Quest Diagnostics Inc: To Acquire Pathai Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis
Quest Diagnostics to Acquire PathAI Diagnostics to Accelerate AI and Digital Pathology Adoption in Cancer Diagnosis; Forms Licensing Agreements With PathAI
Transaction is part of wide-ranging collaboration to combine Quest's oncology expertise and scale with PathAI's AI and digital pathology innovations to speed diagnosis, improve quality and reduce cost
Comments
Quest Diagnostics' consistent ROCE and increased capital employed over the past five years suggest steady reinvestment at good returns. This trend, reflected in the stock's strong performance, is expected to continue.
Returns On Capital At Quest Diagnostics (NYSE:DGX) Have StalledThe acquisition aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions and expands its ability to serve providers and patients in Ohio and Pennsylvania.
The CEO of Quest Diagnostics, Jim Davis, believes Yuri Fesko's deep medical expertise and patient-care advocacy will greatly contribute to the company's strategic decisions. His appointment especially bolsters Quest's efforts to improve customer experiences via diagnostic innovations.
Quest Diagnostics shows favorable metrics with robust reinvestment strategies. Significant earnings growth and an anticipated rise in future ROE, despite a higher payout ratio, hint at other growth factors.
Since he will be retiring, I wanted to highlight his unusual trading while in Congress for 40 years.
He became a millionaire many times over on a modest federal salary from trading.
Take a look:
Thomas Carper bought 30k in $ProShares Short QQQ(PSQ.US$ , an ultrashort $Invesco QQQ Trust(QQQ.US$ index, on July 13 2023.
He hedged/shorted in the past with great results with $Advisorshares Trust Ranger Equity Bear Etf(HDGE.US$ , ...
He became a millionaire many times over on a modest federal salary from trading.
Take a look:
Thomas Carper bought 30k in $ProShares Short QQQ(PSQ.US$ , an ultrashort $Invesco QQQ Trust(QQQ.US$ index, on July 13 2023.
He hedged/shorted in the past with great results with $Advisorshares Trust Ranger Equity Bear Etf(HDGE.US$ , ...
4
6
Read more